In light of the current situation with COVID-19, we would like to take this opportunity to assure you that plans have been put into place to ensure business continuity at Biofortuna.
We remain 100% guided by the advice of the UK Government and public health bodies on the appropriate course of action. Working within that guidance, our attitude very much remains one of “business as usual”. Biofortuna play a important role in the IVD supply chain. As a global outsourcing partner to some of the world’s leading diagnostic companies, we manufacture, and provide components for, IVD kits with applications in infectious disease, tissue transplantation and cancer diagnostics in addition to our own SSPGo™ products for HLA typing. These tests have significant clinical relevance for vulnerable or potentially vulnerable individuals.
Naturally, as an ISO:13485 accredited and FDA-registered facility, we have been inundated with requests for development services, reagents and manufacturing support to address the novel SARS-CoV-2 virus. We already have a number of customer specific projects underway in parallel with the Biofortuna range of products for assay development and assay stabilisation and Biofortuna’s genomic services.
At this present time, all of our approved suppliers are still operating as normal and we anticipate any impact to be negligible. We will, however, keep you up to date if the situation changes.
In these difficult times, remember to look after yourself and others.
Comments are closed.